SGLT2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Systematic Review and Meta-Analysis - Data and Code
Abstract
Data, code, and supplementary materials for the systematic review and meta-analysis: "Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis with Trial Sequential Analysis" MAIN FINDINGS:- Primary outcome (CV death or HF hospitalization): HR 0.80 (95% CI 0.73-0.87)- Trial Sequential Analysis: Conclusive evidence (146% of required information size)- NNT: ~58 patients per year- 2 dedicated HFpEF trials included (DELIVER, EMPEROR-Preserved; n=12,251) CONTENTS:- Extracted study data (CSV)- Complete R analysis scripts- All manuscript and supplementary figures (17 PDFs)- RMarkdown source files- Data dictionary REGISTRATION: PROSPERO CRD420251167908 Keywords: SGLT2 inhibitors, heart failure, preserved ejection fraction, HFpEF, meta-analysis, trial sequential analysis, dapagliflozin, empagliflozin
How strong is the evidence?
Evidence Hub reads this as a meta-analysis. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 12,251 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.